Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings that showed, for adults with locally advanced cancer across five different disease sites, proton chemoradiotherapy was associated with significantly reduced acute adverse events, with no difference in disease-free or overall survival (Abstract 6521).
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, and Hope S. Rugo, MD, of the University of California, San Fran...
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, University of Paris-Sud, discusses study findings showing that not only does darolutamide prolong metastasis-free survival, i...
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss phase III...
Mark J. Levis, MD, PhD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses the effect of gilteritinib on survival in patients with FL...
Thomas J. George, MD, of NRG Oncology and The University of Florida Health Cancer Center, discusses the initial phase II results from a clinical trial using total neoadjuvant...
